Enanta Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on the stock and has a $20.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brandon Folkes has given his Buy rating due to a combination of factors related to how the recent RSV headlines intersect with Enanta’s lead asset, zelicapavir. He argues that the FDA’s renewed focus on RSV monoclonal antibodies in healthy infants has little direct read‑through to an oral antiviral used to treat active infection, which follows a distinct regulatory path and benefit‑risk framework.
Folkes also notes that any decline in preventive monoclonal use could increase RSV infections and thereby enlarge the addressable treatment market that zelicapavir targets. Coupled with clearer potential Phase 3 regulatory requirements and a DCF-based valuation that incorporates a meaningful but risk-adjusted contribution from zelicapavir, he sees the recent news flow as fundamentally supportive of Enanta’s long-term value despite acknowledged clinical, regulatory, and commercial risks.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ENTA in relation to earlier this year.